Scarica l'app Stockscreener
3.53
2.49%
-0.09
Dopo l'orario di chiusura:
3.53
Precedente Chiudi:
$3.62
Aprire:
$3.66
Volume 24 ore:
2.59M
Relative Volume:
2.33
Capitalizzazione di mercato:
$289.77M
Reddito:
$531.00K
Utile/perdita netta:
$-99.96M
Rapporto P/E:
-1.6105
EPS:
-2.1919
Flusso di cassa netto:
$-98.96M
1 W Prestazione:
+6.65%
1M Prestazione:
-26.15%
6M Prestazione:
-38.29%
1 anno Prestazione:
-47.31%
Intervallo 1D:
$3.495
$3.6885
Intervallo di 1 settimana:
$2.98
$3.6885
Portata 52W:
$2.98
$10.99
Lexeo Therapeutics Inc Stock (LXEO) Company Profile
Nome
Lexeo Therapeutics Inc
Settore
Industria
Telefono
(212) 547-9879
Indirizzo
345 PARK AVENUE SOUTH, NEW YORK
Compare LXEO vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LXEO
Lexeo Therapeutics Inc
|
3.53 | 271.71M | 531.00K | -99.96M | -98.96M | -2.1919 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Lexeo Therapeutics Inc Stock (LXEO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-18 | Iniziato | Raymond James | Strong Buy |
| 2025-11-20 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-10-15 | Iniziato | Guggenheim | Buy |
| 2025-07-31 | Iniziato | Oppenheimer | Outperform |
| 2024-06-13 | Iniziato | Robert W. Baird | Outperform |
| 2024-06-06 | Iniziato | H.C. Wainwright | Buy |
| 2023-11-28 | Iniziato | Chardan Capital Markets | Buy |
| 2023-11-28 | Iniziato | JP Morgan | Overweight |
| 2023-11-28 | Iniziato | Leerink Partners | Outperform |
| 2023-11-28 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-11-28 | Iniziato | Stifel | Buy |
Mostra tutto
Lexeo Therapeutics Inc Borsa (LXEO) Ultime notizie
Lexeo Therapeutics Inc (LXEO-Q) Stock Price and News - The Globe and Mail
Lexeo Therapeutics Announces Oral Presentation of LX2006 at - GlobeNewswire
Lexeo Therapeutics at Stifel 2026 Virtual Cardiometabolic Forum: pipeline push - Investing.com UK
Which biotech just closed a Friedreich ataxia pipeline deal for USD 8.3 million upfront and up to USD 13 million more in contingent payments? - kalkine.ca
Developer gains rights to experimental FA therapies in $21M acquisition deal - Friedreich's Ataxia News
Lexeo Therapeutics Finalizes Acquisition of Mantle Therapeutics in $8.3M Cash and Stock Deal - kalkinemedia.com
Form 8K Lexeo Therapeutics Inc For: 29 September By Investing.com - Investing.com Nigeria
Lexeo Therapeutics completes acquisition of Mantle Therapeutics - Investing.com
Lexeo Therapeutics (LXEO) medical chief acquires 2,714 shares through an employee plan - Stock Titan
At $3.39 a share, Lexeo Therapeutics (LXEO) grants its CFO 54,750 stock options. - Stock Titan
Lexeo Therapeutics (LXEO) CEO acquires 2,306 shares through an employee plan and receives a stock option. - Stock Titan
The week in pharma: action, reaction and insight – week to September 25, 2026 - The Pharma Letter
LXEO News | LEXEO THERAPEUTICS INC (NASDAQ:LXEO) - ChartMill
Analysts Offer Insights on Healthcare Companies: Eledon Pharmaceuticals (ELDN), Lexeo Therapeutics, Inc. (LXEO) and Edgewise Therapeutics (EWTX) - The Globe and Mail
Lexeo Therapeutics Price Target Maintained With a $15.00/Share by Leerink Partners - Moomoo
Leerink Partners maintains Outperform rating on Lexeo Therapeutics, $15 price target - TradingView
Lexeo Therapeutics expands position in Friedreich’s ataxia - BioWorld News
Lexeo gains access to Apertura’s gene therapy capsid By Investing.com - Investing.com India
Lexeo Therapeutics, Inc. (LXEO) Stock Price, News, Quote & History - finance.yahoo.com
Lexeo gains access to Apertura’s gene therapy capsid - Investing.com
A gene-delivery tool designed to reach the brain will be available to Lexeo for Friedreich ataxia, a genetic disorder. - Stock Titan
Lexeo Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum - GlobeNewswire
Lexeo to acquire Mantle Therapeutics - The Pharma Letter
Baird reiterates Lexeo Therapeutics stock rating on acquisition deal By Investing.com - Investing.com Australia
Why is Lexeo Therapeutics stock gaining today? By Investing.com - Investing.com Australia
Lexeo Buys Mantle Therapeutics, Inks New Research Deals to Build FA Pipeline - GenomeWeb
Why is Lexeo Therapeutics stock gaining today? - Investing.com
Lexeo stock rises on $21.3M Mantle deal for FA therapies - Investing.com Canada
Raymond James reiterates Strong Buy on Lexeo stock after acquisition By Investing.com - Investing.com Canada
Ericsson, Lexeo Therapeutics And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session - Benzinga
Lexeo Therapeutics to Acquire Mantle Therapeutics for Up to $21.3 Million - Minichart
Lexeo to acquire Mantle Therapeutics for $21.3M By Investing.com - Investing.com Canada
Lexeo to acquire Mantle Therapeutics for $21.3M - Investing.com
Lexeo Therapeutics expands FA pipeline with Mantle acquisition - TipRanks
Lexeo Therapeutics Enters Into Agreement to Acquire Mantle Therapeutics and Announces Multiple New Strategic Collaborations to Expand Leadership in Friedreich Ataxia - The Manila Times
LXEO: Acquisition expands the FA platform with multimodal therapies and up to $21.3M in payments - TradingView
LXEO: Acquisition expands FA treatment platform with new modalities and strategic collaborations - TradingView
Lexeo Therapeutics to Acquire Mantle Therapeutics for $8.3M Upfront, Up to $13M in Milestones - TradingView
Four therapies for a missing brain protein may join Lexeo - Stock Titan
Lexeo Therapeutics Enters Into Agreement To Acquire Mantle Therapeutics And Announces Multiple New Strategic Collaborations To Expand Leadership In Friedreich Ataxia - TradingView
Lexeo Therapeutics, Inc. agreed to acquire Mantle Therapeutics Inc. for $21.3 million . - marketscreener.com
Lexeo Therapeutics at Cantor conference: gene therapy push gains traction By Investing.com - Investing.com Canada
Lexeo Therapeutics to Participate in Upcoming Investor Conferences in September - The Manila Times
Balyasny Asset Management L.P. Expands Stake in Lexeo Therapeuti - GuruFocus
Lexeo Therapeutics (NASDAQ:LXEO) CEO Richard Nolan Townsend Sells 3,345 Shares - MarketBeat
Louis Edward Tamayo Sells 4,117 Shares of Lexeo Therapeutics (NASDAQ:LXEO) Stock - MarketBeat
Lexeo Therapeutics CFO Louis Edward Tamayo Sells 4,117 Shares to Settle RSU Tax Liabilities - Kalkine Media
Lexeo Therapeutics COO Jose Manuel Otero Sells Shares to Cover RSU Tax Liability - Kalkine Media
Lexeo Therapeutics CEO Richard Nolan Townsend Sells 3,345 Shares to Settle RSU Tax Liabilities - Kalkine Media
Lexeo Therapeutics (LXEO) CFO sells shares for RSU taxes - Stock Titan
Lexeo (NASDAQ: LXEO) CEO sale covers RSU tax bill, keeps 374K shares - Stock Titan
Lexeo Therapeutics Inc Azioni (LXEO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Lexeo Therapeutics Inc Azioni (LXEO) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Townsend Richard Nolan | Chief Executive Officer |
Aug 18 '26 |
Sale |
4.95 |
3,345 |
16,562 |
374,472 |
| Otero Jose Manuel | Chief Operating Officer |
Aug 18 '26 |
Sale |
4.96 |
1,304 |
6,464 |
136,178 |
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):